carbamates has been researched along with Blood Coagulation Disorders, Inherited in 1 studies
Blood Coagulation Disorders, Inherited: Hemorrhagic and thrombotic disorders that occur as a consequence of inherited abnormalities in blood coagulation.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hézode, C | 1 |
| Colombo, M | 1 |
| Bourlière, M | 1 |
| Spengler, U | 1 |
| Ben-Ari, Z | 1 |
| Strasser, SI | 1 |
| Lee, WM | 1 |
| Morgan, L | 1 |
| Qiu, J | 1 |
| Hwang, P | 1 |
| Robertson, M | 1 |
| Nguyen, BY | 1 |
| Barr, E | 1 |
| Wahl, J | 1 |
| Haber, B | 1 |
| Chase, R | 1 |
| Talwani, R | 1 |
| Marco, VD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase III Double Blind Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 in Subjects With Chronic HCV GT1, GT4 and GT6 Infection With Inherited Blood Disorders With and Without HIV Co-Infection[NCT02252016] | Phase 3 | 159 participants (Actual) | Interventional | 2014-10-22 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The percentage of participants in the both arms achieving SVR12 (i.e., HCV riboncleic acid [RNA] level below the lower limit of quantification [LLoQ] 12 weeks after completing study therapy) was determined. HCV RNA levels were measured using the Roche COBAS™ Taqman™ HCV Test v2.0 (High Pure System), which has a LLoQ of <15 IU/mL. (NCT02252016)
Timeframe: 12 weeks after completing study therapy (Week 24)
| Intervention | Percentage of participants (Number) |
|---|---|
| Immediate Treatment | 93.5 |
| Deferred Treatment | 91.8 |
The percentage of participants in both arms achieving SVR24 (i.e., HCV RNA level below the LLoQ 24 weeks after completing study therapy) was determined. HCV RNA levels were measured using the Roche COBAS™ Taqman™ HCV Test v2.0 (High Pure System), which has a LLoQ of <15 IU/mL. (NCT02252016)
Timeframe: 24 weeks after completing study therapy (Week 36)
| Intervention | Percentage of participants (Number) |
|---|---|
| Immediate Treatment | 90.7 |
| Deferred Treatment | 91.8 |
An AE is any untoward medical occurrence which does not necessarily have to have a causal relationship with this treatment. (NCT02252016)
Timeframe: Up to Week 12
| Intervention | Percentage of Participants (Number) |
|---|---|
| Immediate Treatment | 0.0 |
| Deferred Treatment | 1.9 |
An AE is any untoward medical occurrence which does not necessarily have to have a causal relationship with this treatment. (NCT02252016)
Timeframe: Up to Week 14
| Intervention | Percentage of Participants (Number) |
|---|---|
| Immediate Treatment | 72.9 |
| Deferred Treatment | 65.4 |
1 trial available for carbamates and Blood Coagulation Disorders, Inherited
| Article | Year |
|---|---|
Elbasvir/Grazoprevir for Patients With Hepatitis C Virus Infection and Inherited Blood Disorders: A Phase III Study.
Topics: Administration, Oral; Adult; Amides; Benzofurans; Biopsy, Needle; Blood Coagulation Disorders, Inher | 2017 |